CEBP Prevention Award Targets
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kasum, C. M.
Right arrow Articles by Ross, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kasum, C. M.
Right arrow Articles by Ross, J. A.
Cancer Epidemiology Biomarkers & Prevention Vol. 12, 534-537, June 2003
© 2003 American Association for Cancer Research

Non-steroidal Anti-inflammatory Drug Use and Risk of Adult Leukemia1

Christine M. Kasum, Cindy K. Blair, Aaron R. Folsom and Julie A. Ross2

Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis, Minnesota 55454 [C. M. K., C. K. B., A. R. F.]; Division of Population Sciences, Dana Farber Cancer Institute, Boston, Massachusetts 02115 [C. M. K.]; and University of Minnesota Cancer Center, Minneapolis, Minnesota 55455 [J. A. R.]


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Epidemiological studies have suggested that regular use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) may be associated with reduced risk of some types of malignancy. Leukemia incidence and self-reported aspirin, as well as other NSAID use, was examined in a prospective cohort of >28,000 postmenopausal women. Eighty-one incident leukemia cases occurred during the period 1993–2000. The multivariate-adjusted relative risk of leukemia was 0.45 (95% confidence interval: 0.27–0.75) for women who reported using aspirin two or more times per week compared with women who reported no use. Similar inverse associations were observed for the two subtypes of leukemia analyzed. In contrast, for women who reported using nonaspirin NSAIDs, the multivariate-adjusted relative risk of leukemia was 1.31 (95% confidence interval: 0.77–2.22). Analyses that excluded cases diagnosed before 1995 did not notably alter results. To our knowledge, this is the first prospective study to examine the association between NSAID use and incident adult leukemia. Although preliminary, the notable differences observed in leukemia risk between aspirin and nonaspirin NSAID use warrant further investigation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Leukemia accounts for ~5% of all newly diagnosed malignancies in the United States (1 , 2) . In adults, the most common types of leukemia are AML,3 chronic myeloid leukemia, and CLL; acute lymphoblastic leukemia is quite rare. Little is known regarding the etiology of leukemia in adults. Benzene, chemotherapeutic drugs, ionizing radiation, and cigarette smoking are known to increase the risk of certain subtypes of leukemia (1 , 3) ; however, taken together, these factors likely account for only a very small proportion of leukemia cases.

Regular use of aspirin or other NSAIDs has been associated with a decreased risk of colon cancer (4, 5, 6, 7, 8) and possibly of other sites (8, 9, 10, 11) . To date, few studies have regarded possible associations between NSAID use and the development of leukemia. This prospective study explored whether regular use of aspirin or other NSAIDs may protect against the development of leukemia in older adult women.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Detailed descriptions of the IWHS have been published elsewhere (12, 13, 14) . Briefly, participants in the IWHS were a random sample of women ages 55–69 years listed on the 1985 State of Iowa driver’s license list. A total of 41,836 women responded to a mail survey in January 1986 (42.7% response rate).

The baseline mail survey assessed medical history, anthropometric data, diet, and risk factors for cancer. Use of aspirin and other NSAIDs were assessed in a 1992 follow-up mail survey. Respondents were asked to complete two questions regarding NSAID use: (a) "How often do you take aspirin?" (several common brand names were provided as examples); and (b) "How often do you take other non-steroidal anti-inflammatory drugs or arthritis medicines?" (Nonaspirin NSAID product names were provided, including common brand names for ibuprofen, naproxen, sulindac, and piroxicam. Respondents were instructed not to include aspirin, acetaminophen, or cortisone-type drugs.) Response options included six categories ranging from never to six or more times per week. Diagnoses of rheumatoid arthritis and osteoarthritis were also assessed in the 1992 follow-up questionnaire. Women were excluded who did not complete the 1992 follow-up questionnaire (n = 8819), did not complete at least one of the NSAID questions (n = 258), or were diagnosed with any malignancy (other than nonmelanoma skin cancer) before 1993 (n = 4535). After these exclusions, 28,224 women comprised the at-risk cohort for leukemia.

Incident cancer was determined using the Health Registry of Iowa, part of the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (15) . Incident cases were identified through computer matching between the 1993–2000 Registry cases and study participants. A total of 81 women in the at-risk cohort was identified as developing leukemia during the 8-year follow-up period. The leukemias included 35 CLL, 28 AML, 5 chronic myeloid leukemia, 4 chronic myelomonocytic leukemia, 4 basophilic, 3 acute not otherwise specified, 1 acute lymphoblastic leukemia, and 1 hairy cell (16) .

Person-years of follow-up were calculated from completion of the 1992 follow-up questionnaire (January 1, 1993) until one of the following events: (a) date of diagnosis of leukemia; (b) date of death (if death occurred in Iowa); (c) date of move from Iowa (exact date, if known) or interval midpoint, if move date uncertain; and (d) the midpoint between the last contact and date of death (if death occurred outside of Iowa). Emigration was ascertained via the follow-up questionnaire in 1987 by an address correction request or via the National Death Index. If none of these events occurred, the women were assumed to be living in Iowa at the end of the follow-up date on December 31, 2000. {chi}2 and t tests were performed to determine whether characteristics differed according to leukemia status. Associations of aspirin and nonaspirin NSAIDs with incident leukemia were calculated from age-adjusted and multivariate RRs, along with 95% CIs using Cox proportional hazards regression (17) . Preliminary analyses were adjusted for age only; subsequent analyses were adjusted for age, smoking (ever/never and pack-years), and education. A Wald {chi}2 test for trend was performed by treating the categorical variables of intake as a continuous variable in the model.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Women who developed leukemia reported significantly less frequent aspirin use than those who did not develop leukemia (Table 1)Citation . In contrast, those who developed leukemia reported more frequent nonaspirin NSAID use than those who did not develop leukemia, although this difference was not statistically significant. No statistically significant differences between cases and noncases were observed for mean age, education level, or smoking.


View this table:
[in this window]
[in a new window]

  		Table 1 Baseline characteristics, aspirin use, and use of other NSAIDs according to leukemia status for 28,224 Iowan women, 1993–2000

 
Significant inverse associations were observed between aspirin use and incident leukemia, when aspirin use was categorized into three groups based on frequency of use (Table 2)Citation . Those who reported using aspirin more than or equal to two times per week were 0.45 times as likely to develop leukemia as those who reported never using aspirin (95% CI: 0.27–0.75). Similar inverse associations, which were statistically significant, were observed when the two major subgroups of leukemia were analyzed separately, i.e., AML and CLL. We also excluded cases (n = 20) diagnosed in the first 2 years of follow-up (1993–1994). Although fewer relationships approached statistical significance, there were no notable differences in results (data not shown).


View this table:
[in this window]
[in a new window]

  		Table 2 RR of leukemia by frequency of aspirin use IWHS 1993–2000

 
In contrast, for nonaspirin NSAID use, there was a nonsignificant positive association observed with all leukemias (more than or equal to two times per week versus none, RR = 1.31, 95% CI: 0.77–2.22; Table 3Citation ). Analyses by subgroups revealed that this was accounted for primarily by AML. For all analyses, the fully adjusted models did not differ significantly from models that were adjusted for age only, nor did they differ from models that included terms for rheumatoid arthritis, osteoarthritis, body mass index, or energy intake.


View this table:
[in this window]
[in a new window]

  		Table 3 RR of leukemia by frequency of nonaspirin NSAID use IWHS 1993–2000

 
Finally, we examined the relation between incident leukemia and NSAID usage categorized as none, aspirin only, nonaspirin NSAIDs only, and both kinds of NSAIDs, with non-NSAID users as the reference group. Women reporting usage of both types of NSAIDs were 0.52 times as likely to develop leukemia as those reporting no usage of any kind of NSAIDs (95% CI: 0.28–0.95), similar to women who reported aspirin usage only (RR = 0.4, 95% CI: 0.22–0.71). In contrast, there was no inverse association observed for women who reported nonaspirin NSAID use only.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In our prospective study, the observed lower risk of leukemia with aspirin use is consistent with numerous studies reporting an inverse association of aspirin with other cancers (4, 5, 6, 7, 8, 9, 10, 11) . No reduction in leukemia risk was associated with use of NSAIDs other than aspirin, contrary to expectations that NSAIDs might have similar effects as a drug class. It should be noted, however, that many studies have not explored NSAIDs separately. Our observation might suggest that properties unique to specific NSAIDs may be etiologically important.

All aspirin-like drugs have antipyretic, analgesic, and anti-inflammatory properties, but there are important differences in their activities (18, 19, 20) . Aspirin (acetylsalicylic acid) and other NSAIDs act as COX inhibitors, thereby inhibiting prostaglandin synthesis and prostaglandin-induced cellular immunity. The COX enzyme exists as two isoforms: (a) COX-1 and (b) COX-2. COX-1 is constitutively expressed in several tissues and is the only isoform expressed in the gastrointestinal tract and platelets. It is primarily responsible for the biosynthesis of eicosanoids protecting the gastric mucosa and the maintenance of platelet function. COX-2 is up-regulated typically in response to inflammation and injury. Aspirin, but not other NSAIDs, irreversibly inhibits COX-1 activity in platelets and platelet aggregation.

Although aspirin has potentially unique properties that may confer a protective effect, it is unclear why nonaspirin NSAIDs had either no effect or the suggestion of a slight increased risk of leukemia, particularly AML. This category comprised several different NSAIDs, including ibuprofen, sulindac, piroxicam, and naproxen, so subgroup analysis was impossible. Although all of these NSAIDs have properties similar to aspirin, they each also have different half-lives, various effects on COX inhibition, and differential effects on specific p450 enzymes (18 , 20) . Moreover, people tend to be less familiar with some of these drugs as compared with aspirin and therefore may report them poorly. Nevertheless, further investigation of this potential association is needed.

Given the preliminary nature of this analysis, several limitations need to be considered. The results of this study are based on only 81 incident leukemia cases that occurred over an 8-year period. Although the prospective nature of this study avoids the problem of differential recall bias, analysis in a larger population is warranted. Although the relatively homogenous nature of our cohort may decrease residual confounding, it may also limit the generalizability of our findings. Additionally, exposure was assessed by self-report; therefore, some misclassification may have occurred. No information was collected regarding duration of use, which some previous studies have suggested may be important (6 , 7) . There is also the possibility that underlying disease could influence NSAID use, particularly aspirin (e.g., one possible explanation for our findings is that persons with compromised platelet function caused by premalignant hematopoeitic dysfunction may avoid aspirin because of bruising or bleeding problems). Analyses that excluded cases diagnosed before 1995, however, did not notably alter the results. Lastly, the similar associations observed for both AML and CLL might be unexpected given that these leukemias have distinctly different biological and clinical behaviors (1) . The biological mechanism(s) by which NSAIDs exert their anticarcinogenic effects, however, is still unclear. In addition to the inhibition of COX-2, other suggested mechanisms include inhibition of angiogenesis, induction of apoptosis, disruption of signal-transduction pathways, and inhibition of oxidative DNA damage (21 , 22) , all of which may influence risk of any malignancy. A strength of this study was the ability to separately examine the effects of aspirin and nonaspirin NSAIDs. Several studies have grouped aspirin and nonaspirin NSAIDs together, preventing observation of potentially differing associations. In addition, we were able to consider several potential confounders in the analyses, including age, education, previous blood transfusion, smoking status, rheumatoid arthritis, and osteoarthritis. In summary, given the growing body of evidence implicating aspirin as a chemopreventive agent and the lack of etiological data with respect to adult leukemia, it will be necessary for other large cohort studies to evaluate NSAID use and leukemia risk to confirm or refute these findings.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by National Cancer Institute Grant R01 CA39742. C. R. Kasum was supported in part by National Cancer Institute Training Grant T32CA09607. Back

2 To whom requests for reprints should be addressed, at University of Minnesota Cancer Center, MMC 422, 554 CCRB, 420 Delaware Street S.E., Minneapolis, MN 55455. Phone: (612) 626-2902; Fax: (612) 626-4842; E-mail: ross{at}epi.umn.edu Back

3 The abbreviations used are: AML, acute myeloid leukemia; NSAID, non-steroidal anti-inflammatory drug; CI, confidence interval; RR, relative risk; IWHS, Iowa Women’s Health Study; COX, cyclooxygenase; CLL, chronic lymphoblastic leukemia. Back

Received 9/19/02; revised 3/ 4/03; accepted 3/ 4/03.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Linet M. S., Cartwright R. A. The leukemias Shottenfeld D. Fraumeni J. F., Jr. eds. . Cancer Epidemiology and Prevention, Ed 2 841-892, Oxford University Press New York 1996.
  2. Greenlee R. T., Hill-Harmon M. B., Murray T., Thun M. Cancer Statistics, 2001. CA Cancer J. Clin., 51: 15-36, 2001.[Abstract/Free Full Text]
  3. Doll R. Cancers weakly related to smoking. Br. Med. Bull., 52: 35-49, 1996.[Abstract/Free Full Text]
  4. Berkel H. J., Holcombe R. F., Middlebrooks M., Kannan K. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Epidemiol. Rev., 18: 205-217, 1996.[Free Full Text]
  5. Reeves M. J., Newcomb P. A., Trentham-Dietz A., Storer B. E., Remington P. L. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol. Biomark. Prev., 5: 955-960, 1996.[Abstract]
  6. Giovannucci E., Egan K. M., Hunter D. J., Stampfer M. J., Colditz G. A., Willett W. C., Speizer F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333: 609-614, 1995.[Abstract/Free Full Text]
  7. Giovannucci E., Rimm E. B., Stampfer M. J., Colditz G. A., Ascherio A., Willett W. C. Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann. Intern. Med., 121: 241-246, 1994.[Abstract/Free Full Text]
  8. Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5: 138-146, 1994.[Medline]
  9. Anderson K. E., Johnson T. W., Lazovich D., Folsom A. R. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J. Natl. Cancer Inst. (Bethesda), 94: 1168-1171, 2002.[Abstract/Free Full Text]
  10. Funkhouser E. M., Sharp G. B. Aspirin and reduced risk of esophageal carcinoma. Cancer (Phila.), 76: 1116-1119, 1995.[Medline]
  11. Harris R. E., Namboodiri K. K., Farrar W. B. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology, 7: 203-205, 1996.[Medline]
  12. Bisgard K. M., Folsom A. R., Hong C. P., Sellers T. A. Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am. J. Epidemiol., 139: 990-1000, 1994.[Abstract/Free Full Text]
  13. Harnack L., Anderson K. E., Zheng W., Folsom A. R., Sellers T. A., Kushi L. H. Smoking, alcohol, coffee, and tea intake and incidence of cancer of the exocrine pancreas: the Iowa Women’s Health Study. Cancer Epidemiol. Biomark. Prev., 6: 1081-1086, 1997.[Abstract]
  14. Folsom A. R., Kaye S. A., Sellers T. A., Hong C. P., Cerhan J. R., Potter J. D., Prineas R. J. Body fat distribution and 5-year risk of death in older women. JAMA, 269: 483-487, 1993.[Abstract/Free Full Text]
  15. United States Department of Health and Human Services, United States Public Health Service. . SEER Program: Cancer Incidence and Mortality in the United States, 1073-1081, National Cancer Institute Bethesda, MD 1984.
  16. WHO. . International Classification of Disease for Oncology, WHO Geneva 1976.
  17. SAS Institute, Inc. . SAS Release 6.9, SAS Institute, Inc. Cary, NC 1997.
  18. Insel P. A. Analgesic-antipyretics and anti-inflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout Gilman A. G. Rall T. W. Nies A. S. Taylor P. eds. . The Pharmological Basis of Therapeutics, Ed. 8 636-681, Pergamon Press, Inc. Elmsford, NY 1990.
  19. Sjödahl R. Extent, mode, and dose dependence of anticancer effects. Am. J. Med., 10: 66S-69S, 2001.
  20. Lacy C. F., Armstrong L. L., Goldman M. P., Lance L. L. . Drug Information Handbook (pocket), 2000–2001 Lexi-Comp, Inc. Hudson, Ohio
  21. Husain S. S., Szabo I. L., Tamawski A. S. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am. J. Gastroenterol., 97: 543-553, 2002.
  22. Hsu C. S., Li Y. Aspirin potently inhibits oxidative DNA strand breaks: implications for cancer chemoprevention. Biochem. Biophys. Res. Commun., 3: 705-709, 2002.



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
A. Bardia, J. O. Ebbert, R. A. Vierkant, P. J. Limburg, K. Anderson, A. H. Wang, J. E. Olson, C. M. Vachon, and J. R. Cerhan
Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality
J Natl Cancer Inst, June 6, 2007; 99(11): 881 - 889.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. L. Lovering, J. P. Ride, C. M. Bunce, J. C. Desmond, S. M. Cummings, and S. A. White
Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin
Cancer Res., March 1, 2004; 64(5): 1802 - 1810.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kasum, C. M.
Right arrow Articles by Ross, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kasum, C. M.
Right arrow Articles by Ross, J. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online